Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development

Introduction

With an aging population and over 55 million dementia cases worldwide, treatments are more needed than ever. However, effective treatments are lacking, with solutions only stalling dementia progress and no real disease-modifying effect.

Development of AT-001

ATI has developed AT-001, a new drug with the potential to stop and revert the disease, and to delay its onset. AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify patients with validated biomarkers.

Mechanism of Action

AT-001 is different in that it prevents the aggregation of amyloid/tau proteins, which are common in many types of dementia.

Clinical Trials

Phase IIa clinical trials have shown strong effects in the treatment of HCCAA.

Future Plans

We will now carry out a registration trial for commercialization in Iceland and POC studies in Europe to obtain NDA in familial dementia. This will inform the treatment of Alzheimer's Disease (60% of dementia cases), potentially changing the lives of millions for the better.